Clovis Oncology Announces Sale of Shares of Common Stock by Selling Stockholders Business Wire BOULDER, Colo. -- December 3, 2013 Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $57.50 per share. All of the shares are being sold by certain existing stockholders who acquired the shares of the Company’s common stock as consideration in connection with the Company’s acquisition of EOS (Ethical Oncology Science) S.p.A. J.P. Morgan Securities LLC is acting as the sole manager for the offering. The selling stockholders have granted J.P. Morgan Securities a 30-day option to purchase up to an additional 300,000 shares of common stock from the selling stockholders to cover over-allotments, if any. All net proceeds from the sale of the common stock will be received by the selling stockholders. The Company will not receive any of the proceeds, and the total number of shares of its outstanding common stock will not change as a result of the offering. The shares of common stock are being sold by the selling stockholders pursuant to an effective shelf registration statement. This offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204. The offering is expected to close on December 9, 2013, subject to customary closing conditions. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Clovis Oncology Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK. Contact: Clovis Oncology, Inc. Anna Sussman, 303-625-5022 email@example.com or Breanna Burkart, 303-625-5023 firstname.lastname@example.org
Clovis Oncology Announces Sale of Shares of Common Stock by Selling Stockholders
Press spacebar to pause and continue. Press esc to stop.